



New investigator-initiated study of the Episealer® knee implant started

Episurf Medical (NASDAQ: EPIS B) today announces the start of a new investigator-initiated clinical study conducted by Prof. H. Vandenneucker at the University hospital in Leuven, Belgium. The study will follow 30 Episealer® patients over 10 years and the goal is to evaluate the efficacy, safety and performance of the Episealer® device in a larger sample size and on the long term.

"We appreciate that this independent study with long-term follow-up of Episealer® patients is initiated. We trust that the study will show the potential of Episealer® as long-term treatment alternative for patients with focal cartilage defects of the knee joint." comments Prof. Leif Ryd, Senior Medical Advisor, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: pål.ryfors@episurf.com

About Episurf Medical

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's *μ*Fidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: wwwepisurf.com.*